Manchester hospital delivers UK's first NHS CAR-T therapy for aggressive blood cancer

What is the background?

Acute lymphoblastic leukaemia (ALL) is an aggressive blood cancer that can progress quickly without effective treatment. CAR-T therapy NHS Manchester access marks a shift toward reprogramming a patient’s own immune cells to fight cancer, rather than relying solely on chemotherapy or a donor transplant.

What happened?

On 2 January 2026, Manchester Royal Infirmary gave a 28-year-old patient from Bury, diagnosed with acute lymphoblastic leukaemia in March 2025, the UK’s first NHS treatment with obe-cel. Obe-cel is a next-generation CAR-T immunotherapy that reprograms a patient’s own immune cells to recognise and destroy cancer cells more effectively than earlier treatments, delivered back to the patient in two separate doses.

Manchester Royal Infirmary treated more patients on the early-phase global FELIX trial than any other single centre — 24 of the 127 participants worldwide — giving the unit direct experience with the therapy ahead of this first NHS-funded use.

How did it happen?

Because Manchester’s unit treated the most FELIX trial patients of any single site, it was inspected by medical regulators from both the United States and Europe before obe-cel’s approval, according to Dr Eleni Tholouli, the trust’s consultant haematologist who led the treatment. That regulatory scrutiny, built on the unit’s trial experience, is part of what allowed Manchester to be first to deliver the treatment once it moved from trial to routine NHS care.

The FELIX trial results showed 77% of patients who received at least one obe-cel infusion achieved remission, with more durable remissions, improved survival rates, and significantly reduced toxicity compared with other immunotherapies.

Why does it matter?

Professor Peter Johnson, NHS National Clinical Director for Cancer, said: “The journey of obe-cel from scientific research in a UK university to a safe, effective, and affordable treatment… is a remarkable one.” A therapy that began as UK university research reaching NHS patients within the same national system shortens the usual gap between scientific discovery and patient access.

A 77% remission rate for an aggressive blood cancer, combined with reduced toxicity compared with earlier immunotherapies, means more patients can complete treatment with a realistic path to full remission rather than facing the harsher side effects of older CAR-T therapies.

What were the key results?

• UK’s first NHS obe-cel treatment delivered 2 January 2026 at Manchester Royal Infirmary
• Patient: 28-year-old from Bury, diagnosed with ALL in March 2025
• Manchester treated 24 of 127 global FELIX trial participants — the most of any single centre
• 77% of patients achieved remission after at least one obe-cel infusion in trials
• Treatment showed improved survival rates and durability versus earlier immunotherapies
• Significantly reduced toxicity compared with other CAR-T immunotherapies
• Obe-cel originated from scientific research at a UK university before reaching NHS patients

What happens next?

Manchester Royal Infirmary plans to expand obe-cel access to further eligible NHS patients following this first treatment.

NHS England is expected to monitor real-world remission and survival outcomes as more patients receive the therapy outside the original trial setting.

Dr Tholouli’s team said it will continue contributing outcome data to inform future CAR-T therapy approvals.

NHS England said other specialist centres may begin offering obe-cel as capacity and training allow.